CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
CardioRenal developed TENOR, a connected medical device that combines multiple innovative technologies to assist patients with chronic illnesses, including CKD, in measuring their blood potassium levels at home. Patients will collect blood for testing at home using Tasso+, a blood collection device with FDA 510(k) Class II medical device clearance. Doctors can then remotely access the measured data, enabling them to effectively control and normalize patient potassium levels.
“This designation is a tremendous recognition by the FDA of our R&D excellence. It will boost our efforts in bringing the TENOR device to the millions of patients who need it,” said Maurice Bérenger, CEO of CardioRenal. “We look forward to working closely with the FDA to start our clinical trials later this year.”
To qualify for this status, the equipment must feature breakthrough technologies, there must be no FDA-approved or cleared alternatives to the device, it must have significant advantages over existing approved or cleared alternatives, or its application must serve the best interests of patients.
“People are increasingly calling for at-home health solutions, and the partnership with CardioRenal is an exciting opportunity to again demonstrate the benefits to patient care,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc., which makes the Tasso+ device. “We look forward to demonstrating that our blood collection device can be used in combination with the TENOR system to obtain a blood sample in a way that is convenient, addresses patient needs and meets FDA standards for potassium analysis. This fits perfectly in our mission to combine clinical excellence and patient-centric solutions.”
The FDA Breakthrough Devices Program helps patients receive timely access to innovative technologies that have the potential to provide more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases and conditions. As part of this program, the FDA will provide CardioRenal with priority review and interactive communication from its experts and senior managers, to assist the company on its path to commercialization in the US.
